August 9, 2026

Hims Q2 Monday + FTC Shadow, Precision Peptide Pen Launch, U Alberta D-GK17 AMP Paper, CagriSema Head-to-Head Miss

Hims Q2 Monday with FTC data-sharing lawsuit context. Precision Peptide Pen launch. U Alberta D-GK17 antimicrobial peptide paper. CagriSema misses tirzepatide.

4 stories · Covering industry, research, clinical-trials

Editor's Note

Sunday's peptide news anchors on three concurrent themes ahead of the Monday Hims & Hers Q2 earnings print. First, the July 29 FTC lawsuit against Hims & Hers Health (NYSE: HIMS) alleges the company shared consumer sensitive health information with Meta Platforms, Snap Inc., and other online advertising platforms through embedded tracking technologies, and separately alleges unauthorized billing charges for prescriptions patients did not order; Los Angeles County and Utah joined the FTC as co-plaintiffs. HIMS shares dropped 10% on the announcement; Bank of America analyst Allen Lutz reiterated Hold and cut the price target to $30 from $37. Wall Street expects Q2 2026 revenue of $698.9 million (+28.3% YoY) with a -$0.05 EPS loss versus the +$0.17 year-ago quarter. Second, The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) announced the August 2026 launch of the Peptide Pen, its second commercial product following the BPC-157 transdermal patch, extending into precision injection delivery for the compounded and OTC peptide markets. Third, a University of Alberta research team published preclinical data on D-GK17, a human-derived antimicrobial peptide targeting bacterial and fungal biofilms, in Cell Biomaterials; the team is developing gel and bandage delivery formulations for skin infections and cancer-treatment-related mouth ulcers. And on the competitive-obesity front, Novo Nordisk's experimental CagriSema (cagrilintide plus semaglutide fixed-dose combination) failed to control blood sugar as effectively as Eli Lilly's tirzepatide in a head-to-head trial of patients with type 2 diabetes, with results contributing to the widening Lilly-Novo franchise gap documented across the Q2 earnings week.

Industry

Hims & Hers Health (NYSE: HIMS) Q2 2026 Earnings Preview for Monday August 10 After Market Close Under the Shadow of the July 29, 2026 Federal Trade Commission (FTC) Lawsuit Alleging the Company Shared Consumer Sensitive Health Information With Meta Platforms, Snap Inc., and Other Online Advertising Platforms Through Embedded Website Tracking Technologies, Plus Separately Alleging Unauthorized Billing Charges for Prescriptions Patients Did Not Order; Los Angeles County and Utah Joined the FTC as Co-Plaintiffs; HIMS Shares Dropped 10% on the July 29 Announcement, and Bank of America Analyst Allen Lutz Cut the Price Target to $30 From $37 (Maintaining Hold); Wall Street Consensus for Q2: $698.9 Million Revenue (+28.3% YoY) and -$0.05 Diluted EPS Loss

Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close under the shadow of the July 29, 2026 Federal Trade Commission (FTC) lawsuit. FTC allegations: the company shared consumer sensitive health information with Meta Platforms, Snap Inc., and other online advertising platforms through embedded website tracking technologies (pixel-based cookie/session tracking) without meeting informed-consent requirements; and separately, that the company charged some patients for prescriptions they did not order. Los Angeles County and Utah joined the FTC as co-plaintiffs, expanding both the geographic exposure and the potential remedy set. HIMS shares dropped 10% on the July 29 announcement. Bank of America analyst Allen Lutz reiterated Hold and cut the price target to $30 from $37 on FTC-lawsuit uncertainty, characterizing the outcome as a small-fee base case. Wall Street consensus for Q2 2026: $698.9 million revenue (+28.3% year-over-year) and -$0.05 diluted EPS loss versus the +$0.17 year-ago quarter. Options traders are pricing an approximate 14.5% post-earnings move in either direction. Analyst focus areas: peptide-compounding revenue trajectory (Leerink pegs $440M peptide sales for full-year 2026), FTC lawsuit financial and operational impact, and branded GLP-1 partnership contribution since Q1 2026.

#hims-hers #hims #q2-2026-earnings-preview #ftc-lawsuit #meta-platforms #snap-inc #consumer-health-information #unauthorized-billing #bofa #allen-lutz #price-target-cut

Industry

The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) Announces the August 2026 Launch of the Peptide Pen as Its Second Commercial Product, Following the Existing BPC-157 Transdermal Patch, Extending the Canadian Peptide Company's Product Line Into Precision Injection Delivery for the Compounded Peptide and OTC Peptide Delivery-Device Markets; The Launch Positions the Company to Address Both the Consumer-Facing Injection Convenience Segment and the Provider-Directed Compounded Peptide Prescription Segment That the July 23-24, 2026 FDA PCAC Vote (6 of 7 Peptides Recommended for the Section 503A Bulks List) Set Up for Substantial Commercial Expansion Once FDA Rulemaking Completes

The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) announced the August 2026 launch of the Peptide Pen, its second commercial product following the existing BPC-157 transdermal patch. The Peptide Pen is a precision injection delivery device for peptide administration, designed to serve both the consumer-facing injection convenience segment and the provider-directed compounded peptide prescription segment. The launch positions the Canadian peptide company to address multiple channels in the peptide delivery ecosystem: over-the-counter (OTC) peptide products where FDA regulation permits, compounded peptides prescribed by state-licensed 503A pharmacies where the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 recommendation (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) sets up substantial commercial expansion once FDA rulemaking completes (typically 12-24 months), and precision injection dosing for adherence-sensitive peptide protocols. The device announcement extends the transdermal-plus-injectable format strategy the company has been developing since the BPC-157 transdermal patch launch. Peptide delivery devices represent a small but growing segment as the broader peptide compounding market matures through the post-PCAC regulatory pathway.

#precision-peptide-company #peptide-pen #peptide-delivery-device #bpc-157 #transdermal-patch #precision-injection #otc-peptides #compounded-peptides

Research

University of Alberta Research Team Publishes Preclinical Data in Cell Biomaterials on D-GK17, a Human-Derived Antimicrobial Peptide That Targets Bacterial and Fungal Biofilms (the Sticky Extracellular Matrix That Often Renders Traditional Antibiotic Treatments Impenetrable), Demonstrating Stability, Non-Toxicity to Human Cells, and Broad-Spectrum Activity Against Multidrug-Resistant Pathogens; The Team Is Filing a Patent Through the University of Alberta and Developing Gel and Bandage Delivery Formulations for Skin Infections and Cancer-Treatment-Related Mouth Ulcers, Extending the Rapidly-Growing Antimicrobial Peptide Therapeutic Category That the FDA PCAC February 2027 Docket Also Advances via the LL-37 (Cathelicidin) Peptide

A University of Alberta research team published preclinical data in Cell Biomaterials on D-GK17, a human-derived antimicrobial peptide that targets bacterial and fungal biofilms. Biofilms are the sticky extracellular matrix bacterial and fungal communities create that render traditional antibiotic treatments substantially less effective; biofilm-associated infections drive a major portion of antimicrobial resistance and hospital-acquired infection burden. D-GK17 demonstrated stability, non-toxicity to human cells, and broad-spectrum activity against multidrug-resistant pathogens in the preclinical work. The team is filing a patent through the University of Alberta and developing gel and bandage delivery formulations for skin infections and cancer-treatment-related mouth ulcers (chemotherapy and radiation-induced oral mucositis is a substantial unmet-need indication in oncology). D-GK17 extends the rapidly-growing antimicrobial peptide therapeutic category, which the FDA PCAC February 2027 docket also advances via the cathelicidin (LL-37) peptide review. The AMP category is under active development across marine-derived (shrimp SALF-based), computational (MAC-AMP AI design system), and human-derived platforms, with cross-cutting applications spanning antimicrobial resistance, cancer therapy, and antiviral therapy.

#university-of-alberta #d-gk17 #antimicrobial-peptide #biofilm #multidrug-resistant #cell-biomaterials #oral-mucositis #skin-infections #gel-formulation #cathelicidin

Clinical Trials

Novo Nordisk's Experimental CagriSema (Cagrilintide Plus Semaglutide Fixed-Dose Combination, Regulatory Filing Submitted December 18, 2025 With Expected FDA Decision Late 2026) Reportedly Failed to Control Blood Sugar as Effectively as Eli Lilly's Tirzepatide (Mounjaro/Zepbound) in a Head-to-Head Phase 3 Trial of Patients With Type 2 Diabetes; The Trial Outcome Contributes to the Widening Lilly-Novo Franchise Gap Documented Across the Q2 2026 Earnings Week With Lilly Q2 Revenue at $23 Billion (+48% YoY) and Novo H1 at 78.49 Billion DKK ($12.09 Billion, +3% Constant Currency With 5% Stock Decline) as the Investor Narrative on Novo's Ability to Defend GLP-1 Franchise Economics Continues to Deteriorate

Novo Nordisk's experimental CagriSema (cagrilintide plus semaglutide fixed-dose combination) reportedly failed to control blood sugar as effectively as Eli Lilly's tirzepatide (Mounjaro/Zepbound) in a head-to-head Phase 3 trial of patients with type 2 diabetes. CagriSema regulatory filing was submitted December 18, 2025 with an expected FDA decision in late 2026 for obesity indication; the type 2 diabetes head-to-head failure complicates the commercial narrative and label-expansion strategy. The trial outcome adds to the widening Lilly-Novo franchise gap documented across the Q2 2026 earnings week: Eli Lilly (NYSE: LLY) Q2 revenue reached $23 billion (+48% year-over-year) with Foundayo (orforglipron oral small-molecule GLP-1) delivering $98 million in its first fully operational commercial quarter and Mounjaro + Zepbound combined at $14.9 billion; Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency) with shares declining 5% on margin-compression concerns despite raised guidance. Investor narrative on Novo's ability to defend GLP-1 franchise economics continues to deteriorate as the amylin analog (cagrilintide) that Novo positioned as its differentiator against tirzepatide's dual GIP/GLP-1 mechanism failed to close the efficacy gap in the head-to-head setting.

#novo-nordisk #cagrisema #cagrilintide #semaglutide #eli-lilly #tirzepatide #mounjaro #zepbound #head-to-head-trial #phase-3 #type-2-diabetes #franchise-gap